Belvedere Trading’s Seres Therapeutics MCRB Stock Holding History

Belvedere Trading’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,100	Closed	-$233K	–	985
2025 Q3	$233K	Buy	+12,100	New	+$193K	﹤0.01%	445
2023 Q4	–	Sell	-750	Closed	-$35.7K	–	919
2023 Q3	$35.7K	Buy	750 +100	+15%	+$7.63K	﹤0.01%	454
2023 Q2	$62.3K	Buy	+650	New	+$70.7K	﹤0.01%	516

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Belvedere Trading's MCRB Position: Q4 2023 in Review

Belvedere Trading sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 24 shares — an estimated $1.12K sold.

Belvedere Trading first reported a position in MCRB in Q3 2020 and held it in 4 quarters. The position peaked at $488K in Q2 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

Belvedere Trading reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 24 Seres Therapeutics shares in Q4 2023, an estimated $1.12K.
Belvedere Trading first reported a position in Seres Therapeutics in Q3 2020 and held it in 4 quarters.
Belvedere Trading's Seres Therapeutics position peaked at $488K in Q2 2021.
102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.